Investigational drug · Phase 3
PRL3-ZUMAB
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Advanced Malignant Solid Tumor, Solid Tumor, Advanced Solid Cancers.
Phase 3Last checked: Nov 20, 2026Latest source record: Apr 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
4 still active
All registered trials
6
Any phase or sponsor naming "PRL3-ZUMAB"
First trial start
2020
Dec 12, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PRL3-ZUMAB", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Malignant Solid Tumor
- Solid Tumor
- Advanced Solid Cancers
- Neovascular Age Related Macular Degeneration
Approved drugs for the same conditions: Wet macular degeneration · Oncology · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "PRL3-ZUMAB" as an intervention, largest first.
- PRL3-Zumab in Patients With Advanced Solid TumorsActive, not recruiting
Intra-IMMUSG Pte LtdIndustry
NCT07541001 · 60 participants (planned) · Start Aug 30, 2021 · Primary completion Jun 1, 2026
Drug: PRL3-ZUMAB · For: Advanced Malignant Solid Tumor
Sites: Hangzhou, China
- Phase II/III Trial of PRL3-Zumab in Advanced Solid Tumor PatientsPivotal-lookingRecruiting
Intra-IMMUSG Pte LtdIndustry
NCT07290088 · 52 participants (planned) · Start Jan 9, 2023 · Primary completion Dec 2026
Drug: PRL3-ZUMAB · For: Advanced Solid Cancers
Sites: Kota Bharu, Malaysia; Kuala Lumpur, Malaysia · 4 sites in all
- A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid TumorsActive, not recruiting
Intra-IMMUSG Pte LtdIndustry
NCT04452955 · 51 participants · Start Dec 12, 2020 · Primary completion Dec 1, 2026
Drug: PRL3-zumab · For: Solid Tumor
Sites: Scottsdale, Arizona; Fullerton, California; Los Angeles, California · 5 sites in all
- A First-in-Human Study of PRL3-ZUMABActive, not recruiting
National University Hospital, SingaporeAcademic, hospital or other
NCT03191682 · 38 participants (planned) · Start Feb 20, 2017 · Primary completion Feb 20, 2027
Drug: PRL3-ZUMAB · For: Advanced Solid Tumors
Sites: Singapore, Singapore
Intra-IMMUSG Pte LtdIndustry
NCT07547228 · 15 participants (planned) · Start Oct 11, 2025 · Primary completion Feb 7, 2027
Drug: PRL3-ZUMAB · For: Neovascular Age Related Macular Degeneration
Sites: Singapore, Singapore
National Cancer Centre, SingaporeAcademic, hospital or other
NCT04118114 · 14 participants · Start Sep 3, 2019 · Primary completion Oct 17, 2025
Drug: PRL3-zumab · For: Gastric Cancer; Hepatocellular Carcinoma; Advanced Solid Tumor
Sites: Singapore, Singapore
Newest research
PubMed records naming it or its code names, newest first.
- PRL3-zumab cancer immunotherapy shows promise for treating neovascular eye diseases.
Ang KH, Thura M, Zeng Q · Expert Opin Investig Drugs 2026
- PRL-3 as a metastasis-associated phosphatase in colorectal cancer: Mechanisms and therapeutic strategies.
Greenstein SJ, Ramlogan-Steel CA, Wise IA, et al. · Clin Exp Metastasis 2025
- PRL3-zumab as an anti-angiogenic therapy in neovascular eye diseases.
Ang KH, Thura M, Tan QSW, et al. · Nat Commun 2025
- The PRL3-zumab paradigm: A multicenter, single-dose-level phase 2 basket clinical trial design of an unconventional cancer immunotherapy.
Park DJ, Thura M, Chiu VK, et al. · Cell Rep Med 2025
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody.
Loh AHP, Thura M, Gupta A, et al. · Mol Ther Oncolytics 2023
- A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.
Chee CE, Ooi M, Lee SC, et al. · Target Oncol 2023
Also in development for Advanced Malignant Solid Tumor
- QLC5508MHB088CPhase 39 trials
Qilu Pharmaceutical Co., Ltd. · Advanced/Metastatic Solid Tumors, Advanced Malignant Solid Tumor, Extrapulmonary Neuroendocrine Carcinoma
- SCTB41Phase 36 trials
Sinocelltech Ltd. · NHL - Non-Hodgkin's Lymphoma, NSCLC (Advanced Non-small Cell Lung Cancer), Advanced Malignant Solid Tumor
- MHB039APhase 24 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Malignant Solid Tumor, Advanced Breast Cancer, Advanced Lung Cancer
- MHB036CPhase 23 trials
Minghui Pharmaceutical (Hangzhou) Ltd · Advanced Breast Cancer, Advanced Malignant Solid Tumor, Advanced Lung Cancer
- Recombinant Human IL1215-PDL1B Oncolytic HSV-1, VG161Phase 23 trials
CNBG-Virogin Biotech (Shanghai) Ltd. · Advanced Malignant Solid Tumor, Sarcoma, Advanced Intrahepatic Cholangiocarcinoma
- PD-L1 monoclonal antibodyPhase 22 trials
Suzhou BlueHorse Therapeutics Co., Ltd. · Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor
- SCTB39-1Phase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor
- SCTB39GPhase 22 trials
Sinocelltech Ltd. · Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.